Core Viewpoint - A class action securities lawsuit has been filed against Viatris Inc. due to alleged securities fraud that negatively impacted investors between August 8, 2024, and February 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Viatris misrepresented the implications of a warning letter from the FDA regarding its Indore, India facility, downplaying it as a "minor headwind" [2]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris' stock price dropped from $11.24 to $9.53 per share, a decline of approximately 15.21% in one day [2]. Group 2: Investor Participation - Investors who suffered losses during the specified timeframe have until June 3, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Viatris Inc. (NASDAQ: VTRS). Shareholders who purchased shares of VTRS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/viatris-inc-loss-submission-form-2/?id=145083&from=3 CLASS PERIOD: August 8, 2024 to ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Viatris Inc. regarding a class action lawsuit related to misleading statements about the company's Indore, India facility inspection and its subsequent financial performance [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Viatris' management misrepresented the significance of a warning letter from the FDA concerning the Indore facility, downplaying it as a "minor headwind" [1]. - Following the announcement of disappointing financial results for Q4 and fiscal year 2024, Viatris attributed its below-expectation guidance to the financial impact of the warning letter and import alert [1]. Financial Impact - On February 27, 2025, Viatris' stock price dropped from $11.24 to $9.53 per share, marking a decline of approximately 15.21% in one day [1]. Class Action Details - Shareholders who purchased shares during the class period from August 8, 2024, to February 26, 2025, are encouraged to register for the class action, with a deadline of June 3, 2025, to seek lead plaintiff status [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

NEW YORK, April 27, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Viatris Inc. securities between August 8, 2024, and February 26, 2025, of the upcoming lead plaintiff deadline on June 3, 2025, for a class action lawsuit related to misleading statements about the company's Indore, India facility inspection [1][4]. Group 1: Class Action Details - Investors who purchased Viatris securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [2]. - The lawsuit alleges that Viatris provided misleading information regarding the FDA's warning letter and import alert affecting eleven products from its Indore facility, which were downplayed as a "minor headwind" [4][5]. Group 2: Misleading Statements and Financial Impact - Defendants allegedly failed to disclose critical information about the timing of the inspection, the duration of remediation efforts, and the financial implications of these actions [5]. - The lawsuit claims that the misleading statements led investors to purchase Viatris securities at artificially inflated prices, resulting in damages when the true details became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company [3].

Core Viewpoint - A lawsuit has been filed against Viatris Inc. and certain senior executives for potential violations of federal securities laws, stemming from misleading statements regarding the company's operational conditions and the impact of a failed FDA inspection on its financial performance [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Western District of Pennsylvania, titled Quinn v. Viatris Inc., et al., No. 25-cv-466, with investors having until June 3, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Viatris securities [2]. Group 2: Company Background and Allegations - Viatris is a global healthcare company that provides medicines to approximately 1 billion patients across over 165 countries [3]. - The complaint claims that Viatris misrepresented the condition of its facilities, stating they were in "good operating condition" and suitable for their intended purposes, while downplaying the significance of a Warning Letter from the FDA following a failed inspection at its Indore, India facility [3][4]. Group 3: Financial Impact - The failed FDA inspection has had a substantial negative impact on Viatris's financial results, preventing the company from manufacturing and distributing key products, including Lenalidomide [4]. - In its Q4 2024 results released on February 27, 2025, Viatris disclosed that the failed inspection would lower 2025 revenue by approximately $500 million and earnings from operations by approximately $385 million [5]. - Following this announcement, Viatris's stock price fell about 15%, from $11.24 per share on February 26, 2025, to $9.53 per share on February 27, 2025 [5].

Group 1 - Viatris Inc. will present at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 5 p.m. PT / 8 p.m. ET [1] - A live webcast of the presentation will be available, with an archived version accessible for a limited time [1] Group 2 - Viatris is a global healthcare company that combines generics and brands to address healthcare needs [2] - The company aims to empower people to live healthier lives, providing access to high-quality medicines for approximately 1 billion patients annually [2] - Viatris has a diverse portfolio of medicines and a global supply chain designed to reach patients effectively [2]

NEW YORK, April 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Viatris investors who were adversely affected by alleged securities fraud between August 8, 2024 and February 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form ...

PHILADELPHIA, April 24, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) on behalf of purchasers of Viatris securities between August 8, 2024 through February 26, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Viatris securities during the Class Period may, no later than JUNE 3, 2025, seek to be appointed as a lead plaintiff representati ...

CLASS PERIOD: August 8, 2024 to February 26, 2025 ALLEGATIONS: According to the complaint, defendants provided investors with material information concerning the failed inspection of Viatris' Indore, India facility. Defendants' statements misrepresented the FDA's issuance of a warning letter and its impact on Viatris' operations. Defendants routinely referred to the impact of the warning letter as a mere "minor headwind" for the Company. On February 27, 2025, Viatris announced its financial results for the ...